Human PXR-mediated induction of intestinal CYP3A4 attenuates 1α,25-dihydroxyvitamin D 3 function in human colon adenocarcinoma LS180 cells

Biochemical Pharmacology

Volumn 84, Issue 3, 2012, Pages 391-401

  Zheng, Xi Emily ^a,d   Wang, Zhican ^a   Liao, Michael Z ^a   Lin, Yvonne S ^a   Shuhart, Margaret C ^b   Schuetz, Erin G ^c   Thummel, Kenneth E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d NASSAU UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

1 ,25 Dihydroxyvitamin D 3; Cytochrome P450 3A4; Human pregnane X receptor; Osteomalacia; Rifampin; TRPV6

Indexed keywords

6',7' DIHYDROXYBERGAMOTTIN; CALCITRIOL; CYTOCHROME P450 2A1; CYTOCHROME P450 3A4; GRAPEFRUIT EXTRACT; MESSENGER RNA; PREGNANE X RECEPTOR; RIFAMPICIN; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 6;

ARTICLE; CALCIUM ABSORPTION; CANCER CELL; CATALYSIS; CONTROLLED STUDY; DRUG MECHANISM; GRAPEFRUIT JUICE; HUMAN; HUMAN CELL; OSTEOMALACIA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; CACO-2 CELLS; CALCIUM; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INDUCTION; HUMANS; RECEPTORS, STEROID; RIFAMPIN; VITAMIN D;

EID: 84861967316     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.04.019     Document Type: Article

References (48)

1. Brodie MJ, Boobis AR, Dollery CT, Hillyard CJ, Brown DJ, MacIntyre I, et al. Rifampicin and vitamin D metabolism. Clin Pharmacol Ther 1980;27:810-4. (Pubitemid 10072969)
2. Pack AM, Morrell MJ. Epilepsy and bone health in adults. Epilepsy Behav 2004;5(Suppl. 2):S24-9. (Pubitemid 38404510)
3. Petty SJ, O'Brien TJ, Wark JD. Anti-epileptic medication and bone health. Osteoporos Int 2007;18:129-42. (Pubitemid 46090218)
4. Holick MF. Resurrection of vitamin D deficiency and rickets. J Clin Invest 2006;116:2062-72. (Pubitemid 44162310)
5. Khanal RC, Nemere I. Regulation of intestinal calcium transport. Annu Rev Nutr 2008;28:179-96.
6. Meyer MB, Watanuki M, Kim S, Shevde NK, Pike JW. The human transient receptor potential vanilloid Type 6 distal promoter contains multiple vitamin D receptor binding sites that mediate activation by 1,25-dihydroxyvitamin D3 in intestinal cells. Mol Endocrinol 2006;20:1447-61. (Pubitemid 43801243)
7. Taparia S, Fleet JC, Peng JB, Wang XD, Wood RJ. 1,25-Dihydroxyvitamin D and 25-hydroxyvitamin D-mediated regulation of TRPV6 (a putative epithelial calcium channel) mRNA expression in Caco-2 cells. Eur J Nutr 2006;45:196-204. (Pubitemid 43781445)
8. Walters JR, Balesaria S, Chavele KM, Taylor V, Berry JL, Khair U, et al. Calcium channel TRPV6 expression in human duodenum: different relationships to the vitamin D system and aging in men and women. J Bone Miner Res 2006;21:1770-7. (Pubitemid 46141232)
9. Balesaria S, Sangha S, Walters JR. Human duodenum responses to vitamin D metabolites of TRPV6 and other genes involved in calcium absorption. Am J Physiol Gastrointest Liver Physiol 2009;297:G1193-97.
10. Bianco SD, Peng JB, Takanaga H, Suzuki Y, Crescenzi A, Kos CH, et al. Marked disturbance of calcium homeostasis in mice with targeted disruption of the Trpv6 calcium channel gene. J Bone Miner Res 2007;22:274-85. (Pubitemid 46167798)
11. Fujita H, Sugimoto K, Inatomi S, Maeda T, Osanai M, Uchiyama Y, et al. Tight junction proteins claudin-2 and -12 are critical for vitamin D-dependent Ca2+ absorption between enterocytes. Mol Biol Cell 2008;19:1912-21.
12. Feldman D, Pike J, Glorieux F. Vitamin D, 2nd ed., Boston, Massachusetts, USA: Elsevier Academic Press; 2005.
13. Sakaki T, Sawada N, Komai K, Shiozawa S, Yamada S, Yamamoto K, et al. Dual metabolic pathway of 25-hydroxyvitamin D3 catalyzed by human CYP24. Eur J Biochem 2000;267:6158-65.
14. Inouye K, Sakaki T. Enzymatic studies on the key enzymes of vitamin D metabolism; 1 alpha-hydroxylase (CYP27B1) and 24-hydroxylase (CYP24). Biotechnol Annu Rev 2001;7:179-94. (Pubitemid 41081529)
15. Kusudo T, Sakaki T, Abe D, Fujishima T, Kittaka A, Takayama H, et al. Metabolism of 20-epimer of 1alpha,25-dihydroxyvitamin D3 by CYP24: species-based difference between humans and rats. Biochem Biophys Res Commun 2003;309:885-92. (Pubitemid 37122612)
16. Xu Y, Hashizume T, Shuhart MC, Davis CL, Nelson WL, Sakaki T, et al. Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25- dihydroxyvitamin D(3): implications for drug-induced osteomalacia. Mol Pharmacol 2006;69:56-65. (Pubitemid 43048893)
17. Zhou C, Assem M, Tay JC, Watkins PB, Blumberg B, Schuetz EG, et al. Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia. J Clin Invest 2006;116:1703-12.
18. Nishimura M, Naito S, Yokoi T. Tissue-specific mRNA expression profiles of human nuclear receptor subfamilies. Drug Metab Pharmacokinet 2004;19:135-49.
19. Nishimura M, Yaguti H, Yoshitsugu H, Naito S, Satoh T. Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi 2003;123:369-75. (Pubitemid 41327466)
20. Weinstein RS, Bryce GF, Sappington LJ, King DW, Gallagher BB. Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsant drug treatment. J Clin Endocrinol Metab 1984;58:1003-9. (Pubitemid 14084009)
21. Pascussi JM, Gerbal-Chaloin S, Drocourt L, Maurel P, Vilarem MJ. The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim Biophys Acta 2003;1619:243-53. (Pubitemid 36163419)
22. Sinz M, Kim S, Zhu Z, Chen T, Anthony M, Dickinson K, et al. Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions. Curr Drug Metab 2006;7:375-88.
23. Faucette SR, Zhang TC, Moore R, Sueyoshi T, Omiecinski CJ, LeCluyse EL, et al. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther 2007;320:72-80. (Pubitemid 46025721)
24. Thummel KE, Brimer C, Yasuda K, Thottassery J, Senn T, Lin Y, et al. Transcriptional control of intestinal cytochrome P-4503A by 1alpha,25-dihydroxy vitamin D3. Mol Pharmacol 2001;60:1399-406. (Pubitemid 33144911)
25. Gupta A, Mugundu GM, Desai PB, Thummel KE, Unadkat JD. Intestinal human colon adenocarcinoma cell line LS180 is an excellent model to study pregnane X receptor, but not constitutive androstane receptor, mediated CYP3A4 and multidrug resistance transporter 1 induction: studies with anti-human immunodeficiency virus protease inhibitors. Drug Metab Dispos 2008;36:1172-80. (Pubitemid 351717476)
26. Wang Z, Senn T, Kalhorn T, Zheng XE, Zheng S, Davis CL, et al. Simultaneous measurement of plasma vitamin D(3) metabolites, including 4beta,25-dihydroxyvitamin D(3), using liquid chromatography-tandem mass spectrometry. Anal Biochem 2011;418:126-33.
27. Higashi T, Yamauchi A, Shimada K. Application of 4-(4-nitrophenyl)-1,2,4- triazoline-3,5-dione to analysis of 25-hydroxyvitamin D3 in human plasma by liquid chromatography/electron capture atmospheric pressure chemical ionization-mass spectrometry. Anal Sci 2003;19:941-3.
28. Aronov PA, Hall LM, Dettmer K, Stephensen CB, Hammock BD. Metabolic profiling of major vitamin D metabolites using Diels-Alder derivatization and ultra-performance liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem 2008;391:1917-30.
29. Ebeling PR, Sandgren ME, DiMagno EP, Lane AW, DeLuca HF, Riggs BL. Evidence of an age-related decrease in intestinal responsiveness to vitamin D: relationship between serum 1,25-dihydroxyvitamin D3 and intestinal vitamin D receptor concentrations in normal women. J Clin Endocrinol Metab 1992;75:176-82.
30. van Hoof HJ, de Sevaux RG, van Baelen H, Swinkels LM, Klipping C, Ross HA, et al. Relationship between free and total 1,25-dihydroxyvitamin D in conditions of modified binding. Eur J Endocrinol 2001;144:391-6. (Pubitemid 32409592)
31. Acocella G. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 1978;3:108-27.
32. Peloquin CA. Serum concentrations of the antimycobacterial drugs. Chest 1998;113:1154-5. (Pubitemid 28223794)
33. Shao A, Wood RJ, Fleet JC. Increased vitamin D receptor level enhances 1,25-dihydroxyvitamin D3-mediated gene expression and calcium transport in Caco-2 cells. J Bone Miner Res 2001;16:615-24. (Pubitemid 32230590)
34. Cui M, Klopot A, Jiang Y, Fleet JC. The effect of differentiation on 1,25 dihydroxyvitamin D-mediated gene expression in the enterocyte-like cell line, Caco-2. J Cell Physiol 2009;218:113-21.
35. Lin YS, Yasuda K, Assem M, Cline C, Barber J, Li CW, et al. The major human pregnane X receptor (PXR) splice variant, PXR.2, exhibits significantly diminished ligand-activated transcriptional regulation. Drug Metab Dispos 2009;37:1295-304.
36. Ebeling PR, Jones JD, Burritt MF, Duerson CR, Lane AW, Hassager C, et al. Skeletal responsiveness to endogenous parathyroid hormone in postmenopausal osteoporosis. J Clin Endocrinol Metab 1992;75:1033-8.
37. Walters JR, Howard A, Lowery LJ, Mawer EB, Legon S. Expression of genes involved in calcium absorption in human duodenum. Eur J Clin Invest 1999;29: 214-9. (Pubitemid 29106312)
38. Zhou C, Poulton EJ, Grun F, Bammler TK, Blumberg B, Thummel KE, et al. The dietary isothiocyanate sulforaphane is an antagonist of the human steroid and xenobiotic nuclear receptor. Mol Pharmacol 2007;71:220-9. (Pubitemid 46020992)
39. Lemay J, Demers C, Hendy GN, Delvin EE, Gascon-Barre M. Expression of the 1,25-dihydroxyvitamin D3-24-hydroxylase gene in rat intestine: response to calcium, vitamin D3 and calcitriol administration in vivo. J Bone Miner Res 1995;10:1148-57.
40. Furuichi T, Kawata S, Asoh Y, Kumaki K, Ohyama Y. Differential time course of induction of 1alpha,25-dihydroxyvitamin D3-24-hydroxylase mRNA expression in rats by 1alpha,25-dihydroxyvitamin D3 and its analogs. Life Sci 1998;62:453-9. (Pubitemid 28018199)
41. Konno Y, Kodama S, Moore R, Kamiya N, Negishi M. Nuclear xenobiotic receptor pregnane X receptor locks corepressor silencing mediator for retinoid and thyroid hormone receptors (SMRT) onto the CYP24A1 promoter to attenuate vitamin D3 activation. Mol Pharmacol 2009;75:265-71.
42. Won CS, Oberlies NH, Paine MF. Influence of dietary substances on intestinal drug metabolism and transport. Curr Drug Metab 11:778-92.
43. Gubbins PO, McConnell SA, Gurley BJ, Fincher TK, Franks AM, Williams DK, et al. Influence of grapefruit juice on the systemic availability of itraconazole oral solution in healthy adult volunteers. Pharmacotherapy 2004;24:460-7. (Pubitemid 38420532)
44. Paine MF, Widmer WW, Pusek SN, Beavers KL, Criss AB, Snyder J, et al. Further characterization of a furanocoumarin-free grapefruit juice on drug disposition: studies with cyclosporine. Am J Clin Nutr 2008;87:863-71. (Pubitemid 351549230)
45. Liu C, Shang YF, Zhang XF, Zhang XG, Wang B, Wu Z, et al. Co-administration of grapefruit juice increases bioavailability of tacrolimus in liver transplant patients: a prospective study. Eur J Clin Pharmacol 2009;65:881-5.
46. Seidegard J, Randvall G, Nyberg L, Borga O. Grapefruit juice interaction with oral budesonide: equal effect on immediate-release and delayed-release formulations. Pharmazie 2009;64:461-5.
47. Nieminen TH, Hagelberg NM, Saari TI, Neuvonen M, Neuvonen PJ, Laine K, et al. Grapefruit juice enhances the exposure to oral oxycodone. Basic Clin Pharmacol Toxicol 107:782-8.
48. Kupferschmidt HH, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995;58:20-8.